Pulmonary infections (PIs) are a major complication of Acute Myeloid Leukemia (AML) treated with hypomethylating agents (HMA). We retrospectively evaluated 147 AML patients treated frontline with HMA in 2 Centers. Total number of HMA cycles was 1397. There were 88 episodes of PI in 64 patients (43.5\%). Thirty-five/147 patients at risk (23.8\%) developed at least 1 episode of early PI (during cycles 1-2). Median OS in patients who developed early PI was 3.3 months (95\% CI 0.8 - 5.8) versus 10.5 months (95\% CI 8.4 - 12.7) in patients without PI or with PI beyond the 2nd cycle (p < .001). Early PIs were an independent factor predicting lower survival (OR 1.94, 95\% CI 1.28 - 2.93; p = .002). In conclusion, early PIs are common in AML patients receiving HMA and are associated with an unfavorable outcome. The results of our study raise the issue of a tailored infection prevention strategy.
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents / Scamuffa, Maria Cristina; Latagliata, Roberto; Carmosino, Ida; Di Veroli, Ambra; Scalzulli, Emilia; Trape, Giulio; Ciotti, Giulia; De Angelis, Gioia; Tartaglia, Germana; Tarnani, Michela; Breccia, Massimo; Girmenia, Corrado. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - (2023). [10.1080/10428194.2023.2239407]
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents
Carmosino, Ida;Scalzulli, Emilia;Tartaglia, Germana;Breccia, Massimo;
2023
Abstract
Pulmonary infections (PIs) are a major complication of Acute Myeloid Leukemia (AML) treated with hypomethylating agents (HMA). We retrospectively evaluated 147 AML patients treated frontline with HMA in 2 Centers. Total number of HMA cycles was 1397. There were 88 episodes of PI in 64 patients (43.5\%). Thirty-five/147 patients at risk (23.8\%) developed at least 1 episode of early PI (during cycles 1-2). Median OS in patients who developed early PI was 3.3 months (95\% CI 0.8 - 5.8) versus 10.5 months (95\% CI 8.4 - 12.7) in patients without PI or with PI beyond the 2nd cycle (p < .001). Early PIs were an independent factor predicting lower survival (OR 1.94, 95\% CI 1.28 - 2.93; p = .002). In conclusion, early PIs are common in AML patients receiving HMA and are associated with an unfavorable outcome. The results of our study raise the issue of a tailored infection prevention strategy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
